Your browser doesn't support javascript.
loading
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
Griesinger, F; Curigliano, G; Thomas, M; Subbiah, V; Baik, C S; Tan, D S W; Lee, D H; Misch, D; Garralda, E; Kim, D-W; van der Wekken, A J; Gainor, J F; Paz-Ares, L; Liu, S V; Kalemkerian, G P; Houvras, Y; Bowles, D W; Mansfield, A S; Lin, J J; Smoljanovic, V; Rahman, A; Kong, S; Zalutskaya, A; Louie-Gao, M; Boral, A L; Mazières, J.
Affiliation
  • Griesinger F; Department of Hematology and Oncology, Pius-Hospital, University of Oldenburg, Oldenburg, Germany.
  • Curigliano G; European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy.
  • Thomas M; Department of Thoracic Oncology, Thoraxklinik, University Heidelberg and Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
  • Subbiah V; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, USA.
  • Baik CS; Division of Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, USA.
  • Tan DSW; Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
  • Lee DH; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Misch D; Lungenklinik Heckeshorn, Helios Clinic Emil von Behring, Berlin, Germany.
  • Garralda E; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Kim DW; Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Republic of Korea.
  • van der Wekken AJ; Department of Pulmonary Medicine, University of Groningen and University Medical Center Groningen, Groningen, Netherlands.
  • Gainor JF; Department of Medicine, Massachusetts General Hospital, Boston, USA.
  • Paz-Ares L; Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Liu SV; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
  • Kalemkerian GP; Division of Hematology/Oncology, University of Michigan, Ann Arbor, USA.
  • Houvras Y; Department of Surgery/Medicine, Weill Cornell Medical College University, New York, USA.
  • Bowles DW; University of Colorado School of Medicine, Aurora, USA.
  • Mansfield AS; Division of Medical Oncology, Mayo Clinic, Rochester, USA.
  • Lin JJ; Department of Medicine, Massachusetts General Hospital, Boston, USA.
  • Smoljanovic V; F. Hoffmann-La Roche, Ltd, Basel, Switzerland.
  • Rahman A; F. Hoffmann-La Roche, Ltd, Basel, Switzerland.
  • Kong S; Genentech Inc., South San Francisco, USA.
  • Zalutskaya A; Blueprint Medicines Corporation, Cambridge, USA.
  • Louie-Gao M; Blueprint Medicines Corporation, Cambridge, USA.
  • Boral AL; Blueprint Medicines Corporation, Cambridge, USA.
  • Mazières J; Institut Universitaire du Cancer, Toulouse, France. Electronic address: mazieres.j@chuc-toulouse.fr.
Ann Oncol ; 33(11): 1168-1178, 2022 11.
Article in En | MEDLINE | ID: mdl-35973665
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Prognostic_studies Limits: Adolescent / Adult / Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2022 Type: Article Affiliation country: Germany
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Prognostic_studies Limits: Adolescent / Adult / Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2022 Type: Article Affiliation country: Germany